INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 336 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $17,742,015 | +97.2% | 259,121 | +99.0% | 0.08% | +93.2% |
| Q1 2024 | $8,997,718 | -56.8% | 130,213 | -55.2% | 0.04% | -63.6% |
| Q4 2023 | $20,824,841 | +98839.8% | 290,931 | -28.0% | 0.12% | -12.3% |
| Q3 2023 | $21,048 | -17.7% | 404,112 | 0.0% | 0.14% | -17.9% |
| Q2 2023 | $25,586 | +76.2% | 404,112 | +50.6% | 0.17% | +66.3% |
| Q1 2023 | $14,521 | -26.5% | 268,363 | -28.1% | 0.10% | -32.2% |
| Q4 2022 | $19,754 | -99.9% | 373,076 | -2.7% | 0.15% | +8.0% |
| Q3 2022 | $17,836,000 | -18.5% | 383,565 | 0.0% | 0.14% | -14.3% |
| Q2 2022 | $21,882,000 | -8.7% | 383,565 | -2.1% | 0.16% | +14.2% |
| Q1 2022 | $23,971,000 | +16.0% | 391,937 | -1.1% | 0.14% | +33.0% |
| Q4 2021 | $20,666,000 | +89.9% | 396,279 | +35.5% | 0.11% | +76.7% |
| Q3 2021 | $10,885,000 | -8.8% | 292,463 | 0.0% | 0.06% | -17.8% |
| Q2 2021 | $11,938,000 | +1265.9% | 292,463 | +1037.0% | 0.07% | +1116.7% |
| Q1 2021 | $874,000 | – | 25,722 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |